Answers are grounded in this paper and cite their sources.
BACKGROUND: The risk of venous thromboembolism is significantly increased during the postnatal period, and pharmacological thromboprophylaxis remains the cornerstone of venous thromboembolism preventive measures. It is well recognized that many women struggle with the parenteral nature of low-molecular-weight heparin. OBJECTIVES: The aim of this phase 4 pharmacokinetic clinical trial was to characterize the maternal and breastmilk pharmacokinetics of rivaroxaban and edoxaban at steady state in volunteer women within 12 weeks of delivery. METHODS: Volunteer breastfeeding women were recruited and, following informed written consent, took rivaroxaban 20 mg daily or edoxaban 60 mg daily for 3 consecutive days, with matched maternal plasma and breastmilk samples obtained over 6 days. Noncompartmental pharmacokinetic analysis was conducted, including computation of the milk:plasma ratio at steady state. Additionally, physiologically based pharmacokinetic analysis was conducted, allowing simulation of expected feeding-infant plasma concentrations following maternal ingestion. ISRCTN registry: ISRCTN5783139. RESULTS: Four women took part, with 2 taking edoxaban and 2 taking rivaroxaban. Rivaroxaban distributed into human breastmilk at low concentrations; the mean breastmilk area under the concentration-time curve at steady state on day 3 was 583 ng/mL.h, and the milk:plasma ratio 0.2. Edoxaban distributed into human breastmilk mirrored the maternal plasma concentration; the mean breastmilk area under the concentration-time curve at steady state on day 3 was 1654 ng/mL.h, and the milk:plasma ratio was 0.9. Physiologically based pharmacokinetic simulations for both drugs show low infant plasma concentrations in fully breastfed infants. CONCLUSION: Our findings provide compelling evidence for using rivaroxaban in breastfeeding women from a feeding-infant's safety perspective. Testing rivaroxaban against low-molecular-weight heparin in a postnatal thromboprophylaxis trial should be considered to establish maternal efficacy and safety. Edoxaban use in breastfeeding women merits further investigation.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: